- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02029287
Hospital-Community-Family-Care Management Platform for Chronic Heart Failure (HCF-CMP-CHF)
July 24, 2019 updated by: Xiang Gu
Remote Prevention and Treatment Based on Community Under the Guidance of Regional Central Hospital for Patients With Chronic Heart Failure
The purpose of this study is to determine whether the Hospital-Community-Family-Care Management Platform for Chronic Heart Failure reduces the mortality, readmission rates and costs of the subjects with CHF.
Study Overview
Status
Unknown
Conditions
Detailed Description
(1) Indication: Chronic Heart Failure.
(2) Objectives: Primary objective is to evaluate the efficacy of the Hospital-Community-Family-Care Management Platform online compared with the regular clinic follow up in subjects with CHF (I-IV class by NYHA, of which class IV without strict bed rest).Secondary objectives is to assess the safety of the Management Platform online in subjects with CHF.
(3) Study design: Prospective, randomized, controlled study with two follow up management groups: 1) the Hospital-Community-Family-Care Management Follow up Online; 2) the regular monthly clinic follow up.
Study population: Totally 1000 male and female subjects with CHF (I-IV functional class according to NYHA classification).
(4) Quality assurance plan that addresses data validation and registry procedures, including any plans for site monitoring and auditing.
(5) Data checks to compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry.
(6) Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources.
(7) Standard Operating Procedures to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis, reporting for adverse events, and change management.
(8) Duration of follow up: The total follow-up time shall be at least 12 months.
(9) Safety Assessment: Safety of the study will be evaluated by the following assessments: 1) Subject and object examinations (during the follow up period and extending up to 2 week after the end of the study) consisting of a subject interview (including direct questioning about adverse events), physical examination, assessment of body weight, Electrocardiogram (ECG) and echocardiogram (UCG), Left ventricular ejection fraction (LVEF), assessed by echocardiography, The N-terminal prohormone of brain natriuretic peptide (NT-proBNP), a peptide hormone whose plasma concentration is inversely related to the severity of HF, NYHA functional status, assessed by subject interview, 6-minute walk distance (6MWD), Quality of life (QoL), assessed by the Minnesota Living with Heart Failure questionnaire (MLHFQ), a validated questionnaire assessing QoL in subjects with heart failure.
2) Evaluation of clinically relevant safety laboratory parameters, such as complete blood count, serum creatinine, electrolytes, and liver enzymes.
Any Adverse Events (AE) or Serious Adverse Events (SAE) and its potential causal relationship with the study will be recorded and evaluated.
Study Type
Interventional
Enrollment (Anticipated)
1000
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Yangzhou, Jiangsu, China, 225001
- Recruiting
- Department of cardiovascular medicine,Northern Jiangsu Hospital
-
Sub-Investigator:
- Lei Sun, Master
-
Sub-Investigator:
- Ye Zhu, Master
-
Sub-Investigator:
- Shuhang Miao, Bachelor
-
Sub-Investigator:
- Yi Zhang, Master
-
Sub-Investigator:
- Zhengyu Bao, Doctor
-
Contact:
- Jianhua Shen, Doctor
- Phone Number: +86 0514 87373367
-
Sub-Investigator:
- Ming Gu, Master
-
Sub-Investigator:
- Hui Li, Bachler
-
Sub-Investigator:
- Fei Hang, Master
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:Inclusion Criteria:to be considered eligible to participate in this study, a subject must meet the inclusion criteria listed below at the time of screening and randomization:
- Male and female are aged 18 years old or over.
- History of CHF for ≥3 months with NYHA functional class I-IV, of which class IV without strict bed rest.
- Left ventricular ejection fraction (LVEF) ≤45% as assessed by echocardiogram. However, LVEF can be above 45% for patients with cardiac insufficiency caused by atrial fibrillation, valvular heart disease, hypertrophic cardiomyopathy and et al;
- Treatment of CHF with stable and optimal pharmacological therapy according to Chinese guidelines for treatment of CHF. In general, optimal treatment will include a beta-blocker and an ACE inhibitor and/or an angiotensin receptor blocker, unless not tolerated. Medical therapy is defined as stable, if the subject has not started a new CHF drug class and the dose of drugs taken have not been changed during the 3 months prior to screening and randomization.
- Ability to understand the requirements of the study and willingness to provide written informed consent (IC), and agreement to abide by the study restrictions and return for the required assessments.
- Subjects are located in our coverage of the remote monitoring system.
Exclusion Criteria:To be eligible for entry into the study, the subject must not meet any of the exclusion criteria listed below at screening and randomization:
- Some secondary cardiomyopathy: hyperthyroid heart disease and anemic heart disease, and et al;
- A history of malignancy, and life expectancy is less than 1 year;
- Severe primary hepatic and renal insufficiency (alanine aminotransferase≥100 u/L, serum creatinine >3.0mg/dL, serum albumin <2.5g/L);
- Refusal to participate;
- Unable to visit outpatient clinics periodically;
- Ambulatory population;
- Patients were considered inappropriate to participate by researchers.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Subjects with CHF follow-up
Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up.In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of CHF self-care management.
They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP.
The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary.
Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of heart failure-related health behaviors.
|
Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital
Other Names:
Subjects with CHF via conventional clinic visit according to the latest relevant guidelines
|
Active Comparator: Subjects with CHF conventional clinic visit
Subjects with standardized treatment according to latest guidelines via conventional visit.
|
Subjects with CHF via conventional clinic visit according to the latest relevant guidelines
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
all cause mortality
Time Frame: one year
|
Number of subjects with all cause death
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Heart failure morbidity
Time Frame: one year
|
number of subjects with heart failure - related visits
|
one year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Engagement of the intervention
Time Frame: 4 months
|
It was assessed objectively via daily Web portal log-ins and use of the mobile APP
|
4 months
|
heart failure worsening
Time Frame: one year
|
Number of subjects requiring drug or dose changes to intensify concomitant therapy due to worsening of heart failure (HF).
|
one year
|
Hospitalization rate
Time Frame: one year
|
Hospitalization rate associated with heart failure
|
one year
|
Average hospitalization time
Time Frame: one year
|
Average hospitalization time associated with heart failure
|
one year
|
Costs of medications
Time Frame: one year
|
Costs of medications associated with heart failure
|
one year
|
Usability of the HCF intervention for patients
Time Frame: 4 months
|
it was assessed based on the Perceived Health Web Site Usability Questionnaire (PHWSUQ-12)
|
4 months
|
Changes of self-management
Time Frame: 4 months
|
Lifestyle and health behaviors of participants were collected by interview
|
4 months
|
Participants perceptions of intervention components
Time Frame: 4 months
|
During the interview, qualitative method was used to examine participants perceptions of intervention components
|
4 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Xiang Gu, Docter, Department of cardiovascular medicine
- Principal Investigator: Jianhua Shen, Docter, Department of cardiovascular medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2013
Primary Completion (Anticipated)
August 1, 2020
Study Completion (Anticipated)
December 1, 2020
Study Registration Dates
First Submitted
December 21, 2013
First Submitted That Met QC Criteria
January 5, 2014
First Posted (Estimate)
January 7, 2014
Study Record Updates
Last Update Posted (Actual)
July 26, 2019
Last Update Submitted That Met QC Criteria
July 24, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BL2013022
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Heart Failure
-
Maastricht University Medical CenterUniversity College Dublin; RWTH Aachen University; Queen's University, BelfastCompletedChronic Heart FailureNetherlands, Germany, Ireland, United Kingdom
-
Wuerzburg University HospitalRecruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseGermany
-
Lithuanian University of Health SciencesCompletedHeart Failure | Chronic Heart Failure | Congestive Heart Failure | Right Ventricular FailureLithuania
-
Jordan Cardio Vascular Research GroupRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureJordan
-
Zensun Sci. & Tech. Co., Ltd.RecruitingChronic Heart FailureChina
-
University Hospital, Clermont-FerrandHospices Civils de Lyon; University Hospital, Grenoble; Hôpital de la Croix-Rousse and other collaboratorsRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureFrance
-
University of Roma La SapienzaUnknownChronic Heart Failure | Decompensated Heart Failure | Morality
-
University Medicine GreifswaldDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)RecruitingChronic Heart FailureGermany
-
Zensun Sci. & Tech. Co., Ltd.Terminated
-
University Hospital, Gentofte, CopenhagenUnknownChronic Heart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IVDenmark
Clinical Trials on Hospital-Community-Family-Care Management Platform Online
-
Northern Jiangsu Province People's HospitalRecruitingAtrial Fibrillation | TelemedicineChina
-
Bispebjerg HospitalDanish Cancer Society; The Novo Nordic Foundation; Lundbeck Foundation; Sygekassernes... and other collaboratorsCompleted
-
Queen Mary University of LondonUniversity College, London; Public Health EnglandCompletedLatent TuberculosisUnited Kingdom
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)Completed
-
KK Women's and Children's HospitalDuke University; Duke-NUS Graduate Medical School; Health Promotion Board, Singapore and other collaboratorsRecruitingPediatric ObesitySingapore
-
University of RochesterUniversity of Colorado, Denver; Massachusetts General Hospital; Stanford UniversityRecruitingParkinson Disease | Multiple System Atrophy | Corticobasal Degeneration | Progressive Supranuclear Palsy | Parkinson's Disease and Parkinsonism | Dementia With Lewy Bodies | Vascular Parkinsonism | Parkinson Disease Dementia | Lewy Body ParkinsonismUnited States
-
Chinese University of Hong KongCompletedMental Health Wellness 1 | Mental Well-being | Mental Health IssueHong Kong
-
Aristotle University Of ThessalonikiCompletedCardiovascular DiseasesGreece
-
Wenwen YinUnknown
-
Boston UniversityNational Institute of Mental Health (NIMH); Children's Hospital of Philadelphia and other collaboratorsCompletedAutism | Developmental Delay DisordersUnited States